5 Analysts Have This to Say About Sarepta Therapeutics
Portfolio Pulse from Benzinga Insights
In the last quarter, 5 analysts have provided bullish and somewhat bullish ratings for Sarepta Therapeutics (NASDAQ:SRPT), with no bearish or indifferent ratings. The company has an average 12-month price target of $186.8, a decrease of 4.53% from the previous average price target of $195.67.
September 26, 2023 | 2:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sarepta Therapeutics received positive ratings from analysts, with an average 12-month price target of $186.8.
The positive ratings from analysts indicate a bullish sentiment towards Sarepta Therapeutics. The average 12-month price target, despite being lower than the previous one, is still a positive indicator as it suggests that analysts believe the stock has potential for growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100